News
Zacks Investment Research on MSN16d
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?Recursion Pharmaceuticals RXRX faced a significant setback in May 2025 after announcing the discontinuation of three key drug candidates — REC-994, REC-2282, and REC-3964 — as part of its broader ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best small cap AI stocks to buy according to analysts. On July 8, ...
SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding ...
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating ...
Guidance remains unchanged, with management projecting "over $100 million in partnership inflows by the end of 2026" and targeting a cash burn below $390 million in 2026. The company anticipates a ...
Zacks Investment Research on MSN3d
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is ...
Recursion Pharmaceuticals ( (RXRX)) just unveiled an announcement. On July 8, 2025, Recursion Pharmaceuticals acquired full ownership of the ENPP1 inhibitor program, REV102, from Rallybio, aiming ...
An agency-by-agency look at how President Donald Trump and his advisors plan to dramatically shrink the federal government.
Sammy Watkins was certainly one of Clemson’s greatest offensive players of the last quarter-century. But where does he rank on our list of the top 25? File/Wilfredo Lee/AP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback